APS patients at higher risk of complications (triple APL positivity) also have higher titres of anti-DI-β2GP1 antibodies [93], suggesting that the specificity of diagnosis of APS may increase when anti-DI-β2GP1 antibodies are included. Here, APOH is linked to acute promyelocytic leukemia.